Erythropoietin Stimulating Agents Policies
CMS has policies that effect the use of Erythropoietin Stimulating Agents in ESRD facilities. To find out more, click on the links below.
Downloads
-
ESA Monitoring Policy, Effective October 1, 2006 (PDF) -
ESA Monitoring Policy, Effective April 1, 2006 (PDF) -
Chapter 11 - End Stage Renal Disease (ESRD) (PDF) -
Chapter 8 - Outpatient ESRD Hospital, Independent Facility, and Physician/Supplier Claims (PDF)